Head-to-Head cancer drug showdown: which combo keeps myeloma at bay longer?

NCT ID NCT03729804

Summary

This study directly compares two different three-drug combinations for people newly diagnosed with multiple myeloma, a blood cancer. It aims to find out which treatment regimen is better at keeping the cancer from progressing and helps patients live longer without their disease getting worse. The trial involves 250 participants and measures how long the treatments work and how deeply they reduce remaining cancer cells.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • University Of Chicago Medicine Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

Conditions

Explore the condition pages connected to this study.